What is irinotecan + Carboplatin + erbitux used for?

irinotecan + Carboplatin + erbitux is indicated for First-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil and radiation therapy., Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil., Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin., Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed oxaliplatin-based chemotherapy., Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine..

Who makes irinotecan + Carboplatin + erbitux?

irinotecan + Carboplatin + erbitux is developed by Pfizer.

What development phase is irinotecan + Carboplatin + erbitux in?

irinotecan + Carboplatin + erbitux is FDA-approved (marketed).

What is the generic name of irinotecan + Carboplatin + erbitux?

irinotecan-carboplatin-erbitux is the generic (nonproprietary) name of irinotecan + Carboplatin + erbitux.

Last reviewed 2026-04-20 · How we verify

irinotecan + Carboplatin + erbitux (irinotecan-carboplatin-erbitux)

Pfizer · FDA-approved active Quality 25/100

Irinotecan-carboplatin-erbitux is a chemotherapy combination marketed by Pfizer Inc. It targets various molecular pathways to treat different types of cancer. The combination is used for first-line treatment of squamous cell carcinoma of the head and neck, recurrent or metastatic SCCHN, and metastatic colorectal cancer. It has shown clinical differentiation in patients who have failed previous treatments. The commercial significance of irinotecan-carboplatin-erbitux is substantial, with $21.2B in revenue. There are no notable pipeline developments for this drug.

At a glance

Generic name	irinotecan-carboplatin-erbitux
Sponsor	Pfizer
Drug class	chemotherapy
Target	topoisomerase I, platinum DNA damage, epidermal growth factor receptor
Therapeutic area	Oncology
Phase	FDA-approved

Approved indications

First-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil and radiation therapy.
Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed oxaliplatin-based chemotherapy.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.
Treatment of metastatic colorectal cancer (mCRC) in combination with fluorouracil and leucovorin in patients who have failed or are intolerant to irinotecan, oxaliplatin, or a fluoropyrimidine.

Common side effects

No common side effects on file.

Drug interactions

Irinotecan
Carboplatin
Irinotecan
Carboplatin
Erbitux (Cetuximab)
Irinotecan
Carboplatin
Erbitux (Cetuximab)
Irinotecan
Carboplatin
Erbitux (Cetuximab)

Key clinical trials

PhII ICb With/Without Erbitux in MBC Pts (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

irinotecan + Carboplatin + erbitux CI brief — competitive landscape report
irinotecan + Carboplatin + erbitux updates RSS · CI watch RSS
Pfizer portfolio CI